Why Tarsus Pharmaceuticals (TARS) Is Up 9.7% After Raising XDEMVY 2026 Sales Guidance And Acquiring Alkeus

• In early August 2026, Tarsus Pharmaceuticals reported second-quarter revenue of US$173.91 million and a net loss of US$18.55 million, while also raising full-year 2026 XDEMVY net product sales guidance to US$685 million–US$705 million.
• The earnings update highlighted strong XDEMVY uptake, with more than 700,000 patients treated since launch and an acquisition of Alkeus Pharmaceuticals to broaden Tarsus’ ophthalmology pipeline.
• We’ll now examine how this stronger XDEMVY sales outlook and recent developments may influence Tarsus’ previously outlined investment narrative.

AI is about to change healthcare. These 43 stocks are working on everything from early diagnostics to drug discovery. The best part – they are all under $10b in market cap – there’s still time to get in early.

Tarsus Pharmaceuticals Investment Narrative Recap

To own Tarsus, you need to believe XDEMVY can support the business while newer assets gradually reduce dependence on a single drug. The raised 2026 XDEMVY sales guidance reinforces that the short term catalyst is continued prescription momentum, while the biggest near term risk remains heavy reliance on one product and the spending needed to support it. The Alkeus acquisition adds diversification potential, but it does not yet change that concentration risk in a material way.

The Alkeus Pharmaceuticals acquisition is the most relevant recent announcement here, because it adds a late stage asset, gildeuretinol, for Stargardt disease on top of XDEMVY’s growth. While this broadens Tarsus’ ophthalmology focus and introduces a future pipeline catalyst, it also brings additional R&D and integration costs that sit against an already loss making profile, which matters when investors weigh today’s XDEMVY driven cash needs against tomorrow’s potential new revenue streams.

Yet beneath the rising XDEMVY guidance, investors should also be aware of the growing exposure to payer pressure and reimbursement risk…

Read the full narrative on Tarsus Pharmaceuticals (it’s free!)

Tarsus Pharmaceuticals’ narrative projects $1.1 billion revenue and $632.5 million earnings by 2029.

Uncover how Tarsus Pharmaceuticals’ forecasts yield a $94.11 fair value, a 45% upside to its current price.

Exploring Other Perspectives

Some of the lowest ranked analysts were already assuming about US$1.1 billion of revenue and roughly US$327 million of earnings by 2029, yet they still worry that payer pressure could squeeze XDEMVY margins more than consensus expects, showing just how differently you and other investors might weigh today’s guidance upgrades against those longer term risks.

Explore 4 other fair value estimates on Tarsus Pharmaceuticals – why the stock might be worth just $84.00!

Form Your Own Verdict

Disagree with existing narratives? Extraordinary investment returns rarely come from following the herd, so go with your instincts.

• A great starting point for your Tarsus Pharmaceuticals research is our analysis highlighting 4 key rewards that could impact your investment decision.
• Our free Tarsus Pharmaceuticals research report provides a comprehensive fundamental analysis summarized in a single visual – the Snowflake – making it easy to evaluate Tarsus Pharmaceuticals’ overall financial health at a glance.

Interested In Other Possibilities?

Don’t miss your shot at the next 10-bagger. Our latest stock picks just dropped:

• Rare earth metals are an input to most high-tech devices, military and defence systems and electric vehicles. The global race is on to secure supply of these critical minerals. Beat the pack to uncover the 28 best rare earth metal stocks of the very few that mine this essential strategic resource.
• The future of work is here. Discover the 37 top robotics and automation stocks leading the charge in AI-driven automation and industrial transformation.
• The best AI stocks today may lie beyond giants like Nvidia and Microsoft. Find the next big opportunity with these 16 smaller AI-focused companies with strong growth potential through early-stage innovation in machine learning, automation, and data intelligence that could fund your retirement.

This article by Simply Wall St is general in nature. We provide commentary based on historical data
and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your
financial situation. We aim to bring you long-term focused analysis driven by fundamental data.
Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material.
Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com